Sonus gives up the fight for US approval of EchoGen
This article was originally published in Clinica
Executive Summary
Sonus Pharmaceuticals has abandoned attempts to get its flagship product, the ultrasound contrast imaging agent EchoGen, approved by the US FDA and has stopped clinical work on the product. Instead, the company will concentrate on much earlier stage development projects in drug delivery and blood substitutes.